SIC
LXRX icon

SJS Investment Consulting’s Lexicon Pharmaceuticals LXRX Stock Holding History

SJS Investment Consulting’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-400
Closed -$185 – 1615
2025
Q1 		$185 Hold
400
– – ﹤0.01% 1459
2024
Q4 		$296 Hold
400
– – ﹤0.01% 1394
2024
Q3 		$628 Hold
400
– – ﹤0.01% 1248
2024
Q2 		$672 Buy
+400
New +$718 ﹤0.01% 1188

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's LXRX Position: Q2 2025 in Review

SJS Investment Consulting sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2025, closing a stake of 400 shares — an estimated $185 sold.

SJS Investment Consulting first reported a position in LXRX in Q2 2024 and held it in 4 quarters. The position peaked at $672 in Q2 2024. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

  • SJS Investment Consulting reported no remaining Lexicon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • SJS Investment Consulting sold 400 Lexicon Pharmaceuticals shares in Q2 2025, an estimated $185.
  • SJS Investment Consulting first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • SJS Investment Consulting's Lexicon Pharmaceuticals position peaked at $672 in Q2 2024.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on SJS Investment Consulting's 13F filing for Q2 2025, filed 15 Jul 2025.